Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCAINAMIDE HYDROCHLORIDE vs NORPACE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Treatment of life-threatening ventricular arrhythmias,Atrial fibrillation,Atrial flutter,Paroxysmal supraventricular tachycardia
Treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia,Off-label: Atrial fibrillation, atrial flutter, supraventricular tachycardia
Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
Terminal elimination half-life: 2.5-5 hours (normal renal function); prolonged to 11-20 hours in renal impairment (e.g., Cr Cl <30 m L/min); clinical context: requires dosing adjustment in renal failure; NAPA half-life: 6-8 hours (normal), up to 40 hours in renal failure.
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Hepatic acetylation via N-acetyltransferase (NAT2) to N-acetylprocainamide (NAPA); CYP2D6 minor pathway.
Extensively metabolized in the liver primarily by CYP2D6; also involves CYP1A2 and CYP3A4 to a minor extent. Active metabolite: desethylnorpace.
Renal: ~50-60% unchanged via glomerular filtration and tubular secretion; hepatic metabolism to N-acetylprocainamide (NAPA, active) accounts for ~15-30% of dose, further eliminated renally; biliary/fecal: negligible (<5%).
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
~15-20% bound to serum albumin and alpha-1-acid glycoprotein; low binding minimizes displacement interactions.
80-90%, primarily to alpha-1-acid glycoprotein and albumin.
Vd: 1.5-2.5 L/kg (total body water); extensive tissue distribution (e.g., heart, liver, kidneys); clinical meaning: large Vd indicates substantial extravascular distribution, requiring loading doses for rapid therapeutic effect.
1.8-3.6 L/kg; large, indicating extensive tissue distribution.
Oral: 75-95% (immediate-release); IM: 100%; sustained-release oral: ~90% (relative to immediate-release).
Oral: 80-90%.
Cr Cl 10-50 m L/min: administer every 6-12 hours. Cr Cl <10 m L/min: administer every 8-24 hours. For IV: reduce maintenance infusion rate proportional to Cr Cl.
GFR 30-50 m L/min: 150 mg every 12-24 hours; GFR 15-29 m L/min: 150 mg every 24-48 hours; GFR <15 m L/min (not on dialysis): 150 mg every 48 hours or 100 mg every 24 hours.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: avoid use or reduce dose by 50-75% with monitoring.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 25-50% with monitoring; Child-Pugh Class C: contraindicated or use with extreme caution.
Oral: 15-50 mg/kg/day divided every 3-6 hours. IV: Loading dose 15-18 mg/kg; maintenance 20-80 mcg/kg/min. Maximum: 100 mg/kg/day.
<1 year: 10-30 mg/kg/day divided every 6 hours; 1-4 years: 10-30 mg/kg/day divided every 6 hours; 4-12 years: 10-30 mg/kg/day divided every 6 hours; 12-18 years: 150-300 mg every 6 hours. Maximum 800 mg/day.
Start with lower doses (e.g., 250 mg oral every 6 hours) due to age-related renal decline. Monitor for hypotension and toxicity. Adjust based on Cr Cl.
Initiate at 100 mg every 6 hours; consider lower doses due to age-related renal decline; monitor for anticholinergic effects and QT prolongation.
May cause severe blood dyscrasias (e.g., agranulocytosis, neutropenia, thrombocytopenia) and drug-induced lupus erythematosus.
None
Monitor CBC regularly; discontinue if blood dyscrasias occur. Prolonged QT interval risk; caution with other QT-prolonging drugs. May exacerbate heart failure or hypotension. Reduce dose in renal impairment.
Proarrhythmic effects (e.g., new or worsened arrhythmias, torsades de pointes),Heart failure exacerbation,Hepatic impairment,Renal impairment,Electrolyte disturbances (hypokalemia, hypomagnesemia),Conduction disturbances (e.g., QT prolongation, heart block)
Complete heart block, second-degree AV block, torsade de pointes, systemic lupus erythematosus, hypersensitivity to procainamide or procaine.
Pre-existing second- or third-degree AV block unless pacemaker is present,Cardiogenic shock,Severe heart failure,QTc interval > 450 ms,Concomitant use of other QT-prolonging drugs,Hypersensitivity to disopyramide or any component
Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, tomatoes) as hyperkalemia may increase proarrhythmic risk. Alcohol may exacerbate hypotension and cardiac effects.
Grapefruit juice may increase disopyramide levels; avoid concurrent intake. High-fat meals may delay absorption; take consistently with or without food. Avoid excessive alcohol, which can exacerbate hypotension and arrhythmias.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placental perfusion; use only if clearly needed. Risk of neonatal arrhythmias if used near term.
First trimester: No evidence of increased risk of congenital malformations in human studies, but animal studies are insufficient. Second and third trimesters: Risk of fetal bradycardia, QT prolongation, and neonatal depression at delivery. Disopyramide may stimulate uterine contractions, increasing risk of preterm labor.
Present in breast milk in low concentrations; M/P ratio approximately 0.4-0.6. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for bradycardia or hypotension.
Disopyramide is excreted in breast milk with an M/P ratio of approximately 1:1.1. The relative infant dose is about 2–10% of the maternal weight-adjusted dose. Monitor infant for bradycardia, QT changes, and hypoglycemia. Alternative agents preferred unless benefit outweighs risk.
No specific dose adjustments recommended; however, increased volume of distribution and renal clearance in pregnancy may require higher doses or more frequent administration to maintain therapeutic levels. Monitor drug levels closely.
Increased renal clearance and volume of distribution in pregnancy may reduce disopyramide serum concentrations. Therapeutic drug monitoring recommended; dose adjustments may be required to maintain efficacy, but empirical increases are not routinely recommended due to risk of uterine contractions and fetal effects. Plasma protein binding is unchanged.
Procainamide is a Class Ia antiarrhythmic. Monitor for lupus-like syndrome (arthralgias, rash) especially in slow acetylators; screen with ANA titer. Torsades de Pointes risk; monitor QTc. Maintain serum potassium >4.0 m Eq/L. Avoid in myasthenia gravis. Adjust dose in renal impairment.
NORPACE (disopyramide) is a Vaughan Williams Class Ia antiarrhythmic with negative inotropic effects; avoid in patients with heart failure or reduced LVEF. Monitor QRS and QT intervals; torsades de pointes risk. Adjust dose in renal impairment. Anticholinergic side effects (dry mouth, urinary retention, blurred vision) are common.
Take exactly as prescribed; do not skip doses.,Report any joint pain, rash, fever, or unexplained bruising immediately.,Avoid driving if you experience dizziness or lightheadedness.,Notify your doctor if you have new or worsening shortness of breath or chest pain.,Do not stop taking abruptly; this may cause a serious irregular heartbeat.
Take exactly as prescribed; do not miss doses or double up.,Avoid driving if you experience blurred vision or dizziness.,Report chest pain, shortness of breath, fainting, or rapid heartbeat immediately.,May cause dry mouth; sugarless gum or candy can help.,Avoid alcohol and grapefruit juice without consulting your doctor.,Do not stop abruptly; gradual tapering may be needed.
"Procainamide is a class IA antiarrhythmic that is primarily metabolized by N-acetyltransferase (NAT) and also undergoes CYP2D6-mediated metabolism. Midostaurin, a multikinase inhibitor used for FLT3-mutated AML, is metabolized mainly by CYP3A4. Procainamide can inhibit CYP3A4, reducing the clearance and increasing plasma concentrations of midostaurin, potentially leading to enhanced toxicity including QT prolongation, hepatotoxicity, and myelosuppression."
"Procainamide, a Class Ia antiarrhythmic, prolongs the QT interval by blocking cardiac sodium channels and delaying repolarization. Paroxetine, a selective serotonin reuptake inhibitor (SSRI), has been associated with QT prolongation, possibly via inhibition of cardiac hERG potassium channels. Concomitant use increases the risk of excessive QT prolongation, potentially leading to torsade de pointes and other ventricular arrhythmias."
"Procainamide, a class Ia antiarrhythmic agent, prolongs the QT interval by blocking cardiac sodium and potassium channels. Pentamidine, used for Pneumocystis pneumonia, also prolongs the QT interval through inhibition of the rapid delayed rectifier potassium current (IKr). Concomitant use can cause additive QT prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with electrolyte disturbances or renal impairment."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCAINAMIDE HYDROCHLORIDE vs NORPACE, answered by our medical review team.
PROCAINAMIDE HYDROCHLORIDE is a Antiarrhythmic (Class Ia) that works by Class Ia antiarrhythmic agent; blocks sodium channels, slowing conduction velocity and prolonging refractory period in atrial and ventricular myocardium.. NORPACE is a Antiarrhythmic (Class Ia) that works by Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCAINAMIDE HYDROCHLORIDE and NORPACE depend on the specific clinical indication. These are both Antiarrhythmic (Class Ia) agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCAINAMIDE HYDROCHLORIDE is: Oral: 250-500 mg every 3-6 hours. IV: Loading dose 15-18 mg/kg infused over 25-30 minutes, then maintenance infusion 1-4 mg/min. Maximum total daily dose: 4 g.. The standard adult dose of NORPACE is: 150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCAINAMIDE HYDROCHLORIDE and NORPACE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCAINAMIDE HYDROCHLORIDE is classified as Category A/B. FDA Pregnancy Category C. First trimester: Limited human data; animal studies suggest potential fetal harm. Second/third trimesters: May cause maternal hypotension reducing placent. NORPACE is classified as Category C. First trimester: No evidence of increased risk of congenital malformations in human studies, but animal studies are insufficient. Second and third trimesters: Risk of fetal bradyca. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.